Efficacy and safety comparison of infrared laser moxibustion and traditional moxibustion in knee osteoarthritis: Study protocol for a Zelen- design randomized controlled non-inferiority clinical trial

Author:

Wang Zhong-yu1,Chen Fang-fang1,Guo Shi-qi1,Xue Ying1,Zhang Jia-chen1,He Jing1,Shi Yu-qing1,OuYang Xia-li1,Liu Ping2,Zhang Yang3,Shuang Shuang4,Chen Yi-xiang4,Li Jiang-tao4,Zhao Bai-xiao5,Han Li1

Affiliation:

1. Beijing University of Chinese Medicine

2. Beijing Electric Power Hospital of the State Grid Corporation of China

3. AMHT Group Aerospace 731 Hospital

4. Chinese Academy of Sciences

5. Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Abstract

Abstract Background Knee osteoarthritis (KOA), which is the most common chronic degenerative joint disease, places substantial burden on public health resources in China. The purpose of this study is to preliminary evaluate whether infrared laser moxibustion (ILM) is non-inferior to traditional moxibustion (TM) in the treatment of KOA. Methods In the designed Zelen-design randomized controlled non-inferiority clinical trial, a total of 74 patients with KOA will be randomly allocated to one of two interventions: ILM treatment or TM treatment. All participants will receive a 6-week treatment and be followed-up for 4 weeks. The primary outcome will be the mean change in pain on the numeric rating scale (NRS). The secondary outcomes will be the pain on the NRS from weeks 1 to 5 after the start of treatment and the changes from baseline to endpoints (weeks 6 and 10) in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), SF-36, knee circumference, and 6-min walking test. In addition, safety assessment will be performed throughout the trial. Discussion The results of our study will help determine whether a 6-week treatment with ILM is non-inferior to TM in patients with KOA, therefore providing evidence for verifying if ILM can become a safer alternative for TM in clinical applications in the future. Trial registration: Clinical Trial Registration Platform (ChiCTR2200065264); Pre-results. Registered on 1 November 2022.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3